ReviewJournal of the American Veterinary Medical Association2017
Update on the use of cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs in horses.
Review in Journal of the American Veterinary Medical Association, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- Functional infrared thermography imaging can be used to assess the effectiveness of Maxicam GelFrontiers in veterinary science · 2024Article
- A Preliminary Study on the Relationship between Gastric Lesions and Anti-Inflammatory Drug Usage in Heavy Pigs.Veterinary sciences · 2023Article
- The Clinical Pharmacology and Therapeutic Evaluation of Non-Steroidal Anti-Inflammatory Drugs in Adult Horses.Animals : an open access journal from MDPI · 2023Review
- Synopsis of the pharmacokinetics, pharmacodynamics, applications, and safety of firocoxib in horses.Veterinary and animal science · 2023Review
- Anti-inflammatory compounds reduce equine herpesvirus type 1 replication and cell-to-cell spread.Frontiers in veterinary science · 2023Article
- Non-Steroidal Anti-Inflammatory Drugs and Associated Toxicities in Horses.Animals : an open access journal from MDPI · 2022Review
- Comparison of Flunixin Meglumine, Meloxicam and Ketoprofen on Mild Visceral Post-Operative Pain in Horses.Animals : an open access journal from MDPI · 2022Article
- Protective Effect of Silibinin on Lipopolysaccharide-Induced Inflammatory Responses in Equine Peripheral Blood Mononuclear Cells, an In Vitro Study.Animals : an open access journal from MDPI · 2020Article
- Sparing the gut: COX-2 inhibitors herald a new era for treatment of horses with surgical colic.Equine veterinary education · 2020Article
- Pharmacokinetics of Intravenous, Intramuscular, Oral, and Transdermal Administration of Flunixin Meglumine in Pre-wean Piglets.Frontiers in veterinary science · 2020Article
- Letter to the Editor: Bias in statistics or bias in equine veterinary medicine?Equine veterinary journal · 2019Article
- Pharmacokinetics of meloxicam after oral administration of a granule formulation to healthy horses.Journal of veterinary internal medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Nonsteroidal anti-inflammatory drugs work through inhibition of cyclooxygenase (COX) and are highly effective for the treatment of pain and inflammation in horses. There are 2 clinically relevant isoforms of COX. Cyclooxygenase-1 is constitutively expressed and is considered important for a variety of physiologic functions, including gastrointestinal homeostasis. Thus, NSAIDs that selectively inhibit COX-2 while sparing COX-1 may be associated with a lower incidence of adverse gastrointestinal effects. Various formulations of firocoxib, a COX-2-selective NSAID, labeled for use in horses are available in the United States. Equine practitioners should know that the FDA limits the use of firocoxib to formulations labeled for horses, regardless of price concerns. In addition, practitioners will benefit from understanding the nuances of firocoxib administration, including the importance of correct dosing and the contraindications of combining NSAIDs. Together with knowledge of the potential advantages of COX-2 selectivity, these considerations will help veterinarians select and treat patients that could benefit from this new class of NSAID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.